Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.
|Articles|August 1, 2003
Waxman-Hatch changes are on the way
Provisions under House and Senate versions of prescription drug benefits legislation and their impact on FDA final rules regarding generic drug approvals under the Waxman-Hatch Act.
Advertisement
Advertisement
Related to this article
Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.
Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.
Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
Advertisement
Advertisement
Trending on Drug Topics
1
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
2
FDA Approves AbbVie's Juvmo for Parkinson Disease
3
Why Pharmacy is a Cornerstone of Public Health in the US
4
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
5